Author: Dr. David Lowemann

Coverage Inconsistent for Popular Weight-Loss Drugs

Supplies of high-demand obesity treatments are improving, but that doesn’t mean it’s easier to get them. Many employers and insurers are scaling back coverage of Wegovy and Zepbound and a key government program, Medicare, doesn’t cover the drugs for obesity. Meanwhile, some… Read Full Article (External Site) Dr. David LowemannDr. David Lowemann, M.Sc, Ph.D., is […]

Published on February 24, 2025

Genetic evidence that diabetes drug GLP-1 receptor agonists achieve weight loss primarily by reducing fat mass more than muscle

Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications widely used in the treatment of type 2 diabetes (T2D), have shown significant effectiveness in both lowering blood sugar levels and aiding weight loss due to their unique pharmacological mechanisms. A research team assessed the impact of […]

Published on February 24, 2025

Rare Syndrome Linked to COVID Vaccine

Recent research points to a new side effect of the COVID-19 vaccination. A small study found that some people can develop a troubling condition called post-vaccination syndrome after getting the COVID shot. The study, conducted by researchers from Yale School of Medicine,… Read Full Article (External Site) Dr. David LowemannDr. David Lowemann, M.Sc, Ph.D., is […]

Published on February 24, 2025